Sep 30, 2020

Semler Scientific Q3 2020 Earnings Report

Semler Scientific's financial performance rebounded from the effects of the COVID-19 pandemic.

Key Takeaways

Semler Scientific reported financial results for the three and nine months ended September 30, 2020. The company's financial performance rebounded from the effects of the COVID-19 pandemic.

Financial performance rebounded from COVID-19 pandemic effects.

Continued profitability and generation of cash from operating activities expected.

Increased spending to support anticipated growth in business expected.

Actively trying to improve services and economics to the medical community.

Total Revenue
$10.7M
Previous year: $8.9M
+20.5%
EPS
$0.61
Previous year: $0.96
-36.5%
Gross Profit
$9.91M
Previous year: $7.93M
+25.0%
Cash and Equivalents
$16.8M
Previous year: $8.54M
+96.6%
Free Cash Flow
$3.52M
Previous year: $4.67M
-24.7%
Total Assets
$28M
Previous year: $18.9M
+48.7%

Semler Scientific

Semler Scientific

Forward Guidance

Semler Scientific expects continued profitability and generation of cash from operating activities, as well as increased spending to support anticipated growth in its business for the remainder of 2020 and in 2021. It is the company’s intent to grow revenues at a faster rate than expenses and to remain profitable. However, there remains some uncertainty as to state and local governments continuing to revise restrictions related to COVID-19.

Positive Outlook

  • Continued profitability expected.
  • Generation of cash from operating activities expected.
  • Increased spending to support anticipated growth in business expected.
  • Intent to grow revenues at a faster rate than expenses.
  • Intent to remain profitable.

Challenges Ahead

  • Uncertainty as to state and local governments continuing to revise restrictions related to COVID-19.
  • Semler Scientific intends to manage its expenses and other costs in line with changes in revenues and cash position during these uncertain times.